Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589865 | 1.00 | CYP3A4 (0.46) | CYP3A4CYP1A2HIF1AALDH1A1TDP1 | |
| SCHEMBL4345319 | 0.85 | KMT2A (0.54) | CYP3A4CYP1A2HIF1AALDH1A1TDP1 | |
| SCHEMBL4345317 | 0.85 | KMT2A (0.54) | CYP3A4CYP1A2HIF1AALDH1A1TDP1 | |
| SCHEMBL4155877 | 0.83 | HTT (0.47) | ALDH1A1TDP1MAPTLMNAKMT2A | |
| SCHEMBL4155875 | 0.83 | HTT (0.47) | ALDH1A1TDP1MAPTLMNAKMT2A | |
| SCHEMBL3594651 | 0.81 | CYP1A2 (0.48) | CYP3A4CYP1A2HIF1AALDH1A1TDP1 | |
| SCHEMBL3589279 | 0.81 | CYP1A2 (0.48) | CYP3A4CYP1A2HIF1AALDH1A1TDP1 | |
| SCHEMBL3589274 | 0.81 | CYP1A2 (0.48) | CYP3A4CYP1A2HIF1AALDH1A1TDP1 | |
| SCHEMBL16325820 | 0.78 | HTT (0.38) | CYP3A4CYP1A2HIF1AALDH1A1TDP1 | |
| SCHEMBL4173663 | 0.77 | ALDH1A1 (0.56) | CYP3A4CYP1A2HIF1AALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| EP-2074127-A1 | PYRAZOLO [1, 5-A]PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008037459-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008037459-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | CYP3A4 3245/4885CYP1A2 1967/4885HIF1A 665/4885 |
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | CYP3A4 3372/4885CYP1A2 3961/4885HIF1A 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.